BLI Banque de Luxembourg Investments Reduces Position in IQVIA Holdings Inc. $IQV

BLI Banque de Luxembourg Investments trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 55,825 shares of the medical research company’s stock after selling 5,405 shares during the quarter. BLI Banque de Luxembourg Investments’ holdings in IQVIA were worth $12,712,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Claret Asset Management Corp increased its position in shares of IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after acquiring an additional 49 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. increased its position in shares of IQVIA by 3.3% during the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after acquiring an additional 58 shares during the last quarter. Brookstone Capital Management increased its holdings in IQVIA by 2.2% in the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after buying an additional 63 shares during the last quarter. Private Advisor Group LLC increased its holdings in IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 63 shares during the last quarter. Finally, Keybank National Association OH increased its holdings in IQVIA by 0.7% in the fourth quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after buying an additional 67 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Truist Financial lowered their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Evercore reissued an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Royal Bank Of Canada assumed coverage on IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Finally, Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $224.13.

IQVIA Stock Performance

Shares of IQV stock opened at $183.64 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business has a 50 day moving average of $172.42 and a two-hundred day moving average of $194.55. IQVIA Holdings Inc. has a 52 week low of $151.58 and a 52 week high of $247.04. The company has a market cap of $30.65 billion, a P/E ratio of 22.76, a PEG ratio of 1.57 and a beta of 1.21.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the firm posted $2.70 earnings per share. IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.